Equities research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.
A number of other brokerages also recently weighed in on DBVT. HC Wainwright raised their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Tuesday, December 10th.
Get Our Latest Analysis on DBVT
DBV Technologies Stock Up 29.8 %
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
See Also
- Five stocks we like better than DBV Technologies
- Using the MarketBeat Dividend Yield Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is a support level?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Best Aerospace Stocks Investing
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.